Russell-Welsh Hosts Bay Area Biomedical Investment Conference July 7th and 8th
SAN MATEO, Calif.--(BW HealthWire)--July 1, 1999--
Dr. Laura Tyson, Former Clinton Economic Advisor and Current Dean
of the Haas School of Business, to Moderate Panel Discussion on
Consolidation
Next week, Russell-Welsh, Inc., a Bay Area life science communications firm, will be hosting the Bay Area Biomedical Investment Conference at the San Mateo Marriott.
The free conference, which features 21 local public and private biotechnology companies, is open to buy-side and sell-side analysts, institutional investors, portfolio managers, venture capitalists and members of the media.
Dr. Laura Tyson, former chief economic advisor to President Clinton and current dean of the Haas School of Business at the University of California-Berkeley, will moderate a panel discussion focusing on consolidation in the biotechnology industry. Panelists include: Paul Freiman, president and CEO of Neurobiological Technologies; John Walker, chairman and CEO of Axys Pharmaceuticals; Kurt von Emster, portfolio manager for Franklin Templeton; Michael Becker, portfolio manager for Wayne Hummer Investments and editor of the monthly newsletter Beck on Biotech; and Teresa Corbin, partner of the law firm Howrey and Simon.
A second luncheon panel will examine the future of biotech financing from the perspective of Wall Street. Panelists include investment bankers Farah Champsi, managing director at BancBoston Robertson Stephens; Linda Rubinstein, senior vice president at Lehman Brothers; Ira Leiderman, senior vice president at Gerard Klauer Mattison; and Thomas Dietz, Ph.D, senior managing director of Pacific Growth Equities. Jon Saxe, director of Protein Design Labs, will moderate.
This year's conference presents two showcases: "drug discovery tools and services" and "drug research and development." PE Biosystems (PEB) will lead off the discovery showcase, which features bioinformatics, genomics, proteomics and biochip companies such as LJL BioSystems (LJLB), Ciphergen Biosystems, Pangene, Cytokinetics, Entelos, BioSource International (BIOI), RiboGene (RBO) and Vistagen.
SangStat (SANG) will head up the drug research and development showcase, which includes companies involved in all stages of the development process -- from pre-clinical research to product launch -- in disease areas such as cancer, organ transplant rejection, Parkinson's disease, stroke, arthritis, diabetes, hepatitis, psoriasis and scleroderma. Presenting companies include: Cell Genesys (CEGE), Connetics (CNCT), SuperGen (SUPG), Axys Pharmaceuticals (AXPH), SciClone Pharmaceuticals (SCLN), Microcide Pharmaceuticals (MCDE), Calydon, Pherin Pharmaceuticals, Centaur Pharmaceuticals, Metabolex and InterMune Pharmaceuticals.
Russell-Welsh is a full-capability communications firm providing counseling and/or services in the areas of investor relations, shareholder communications, public relations, media relations, marketing publicity, government affairs, community relations, employee communications and strategic communications planning. The firm, headquartered in San Mateo, focuses exclusively on emerging biotechnology, drug delivery, medical device and diagnostic companies. |
